Bayer challenges Indian ruling on Nexavar patent
German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple of months ago issued what was the first compulsory license in India to a generic drug manufacturer, Natco Pharmaceuticals (524816: BY), for its kidney and liver cancer drug Nexavar (sorafenib tosylate) under section 84 (1) (b) of the country’s Patents Act (The Pharma Letter march 13).
A spokesman at Bayer’s German headquarters told TPL in an e-mailed statement: “We strongly disagree with the conclusions of the Patent Controller of India and have appealed his order on May 4 2012 with the Intellectual Property Appellate Board. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients.
Order damages international patent system, endangers research
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze